Originally Posted by
Maxtrade
The thing with PEB is when it rallies it rallies hard and fast. So if you aren't already in then overnight can miss out on large gains.
For example from May 29th - June 19th 2020 an increase in share price of 150%
From May to July 2020 increased 525%
From Aug to Dec 2020 another 90%
From March 2021 to April 2021 increased another 20%
From May 2021 to Aug 2021 increased another 20%
From Aug 2021 to Sept 2021 increased another 10%
Point being sold gains abruptly off short periods of time.
All it takes is for one of the partnerships to flourish this year (most likely in the US) and with that announcement would see a huge rally again in SP. With how far the current SP has fallen back it would in turn now be highly feasible to see an abrupt rally in SP of 220% pushing SP back up to the 1.4/1.5 with such news. That would be a gain we wouldn't want to miss out on sitting on the sidelines. The fact the instos are NOT selling is also positive. Cancer diagnostics and other health related issues that have been on the back burner during Covid, will ramp back up too the forefront as we now transition out of Covid globally. The states are already seeing more cancer and heart related patients prioritising. How many of us have put off checkups, skin cancer scans, prostate checkups, etc even dental appointments during Covid times. Normality will bring important matters such as cancers back to where they should be, top priority. The fact remains CX-bladder still offers a unique viable screening method that is just getting implemented and utilised in its largest market the US. The fact they were able to gain any traction during the last two years of Covid should be looked upon positively. The market can be harsh on SP with so many retail investors now, selling out of fear, buying out of FOMO. PEB still offers what it has, that has not changed and will continue to grow.